640 related articles for article (PubMed ID: 27440212)
1. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
Citrome L
Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
[TBL] [Abstract][Full Text] [Related]
2. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy.
Citrome L
Adv Ther; 2013 Feb; 30(2):114-26. PubMed ID: 23361833
[TBL] [Abstract][Full Text] [Related]
3. Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression.
Veselinović T; Paulzen M; Gründer G
Expert Rev Neurother; 2013 Nov; 13(11):1141-59. PubMed ID: 24175719
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of action of cariprazine.
Stahl SM
CNS Spectr; 2016 Apr; 21(2):123-7. PubMed ID: 26956157
[TBL] [Abstract][Full Text] [Related]
5. Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy.
Citrome L
Adv Ther; 2013 Feb; 30(2):102-13. PubMed ID: 23361832
[TBL] [Abstract][Full Text] [Related]
6. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
[TBL] [Abstract][Full Text] [Related]
7. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability.
Citrome L
Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):193-206. PubMed ID: 23320989
[TBL] [Abstract][Full Text] [Related]
8. Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator.
McEvoy J; Citrome L
Clin Schizophr Relat Psychoses; 2016; 9(4):177-86. PubMed ID: 26757416
[TBL] [Abstract][Full Text] [Related]
9. Cariprazine for bipolar depression: What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2019 Oct; 73(10):e13397. PubMed ID: 31355510
[TBL] [Abstract][Full Text] [Related]
10. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.
Gründer G
Curr Opin Investig Drugs; 2010 Jul; 11(7):823-32. PubMed ID: 20571978
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies.
Earley W; Durgam S; Lu K; Laszlovszky I; Debelle M; Kane JM
Int Clin Psychopharmacol; 2017 Nov; 32(6):319-328. PubMed ID: 28692485
[TBL] [Abstract][Full Text] [Related]
12. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
13. Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study.
Earley W; Burgess MV; Rekeda L; Dickinson R; Szatmári B; Németh G; McIntyre RS; Sachs GS; Yatham LN
Am J Psychiatry; 2019 Jun; 176(6):439-448. PubMed ID: 30845817
[TBL] [Abstract][Full Text] [Related]
14. Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine.
Kiss B; Némethy Z; Fazekas K; Kurkó D; Gyertyán I; Sághy K; Laszlovszky I; Farkas B; Kirschner N; Bolf-Terjéki E; Balázs O; Lendvai B
Drug Des Devel Ther; 2019; 13():3229-3248. PubMed ID: 31571826
[TBL] [Abstract][Full Text] [Related]
15. Cariprazine: First Global Approval.
McCormack PL
Drugs; 2015 Nov; 75(17):2035-43. PubMed ID: 26510944
[TBL] [Abstract][Full Text] [Related]
16. Cariprazine: A Review in Schizophrenia.
Garnock-Jones KP
CNS Drugs; 2017 Jun; 31(6):513-525. PubMed ID: 28560619
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.
Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
Schizophr Res; 2014 Feb; 152(2-3):450-7. PubMed ID: 24412468
[TBL] [Abstract][Full Text] [Related]
18. Cariprazine in Three Special Different Areas: A Real-World Experience.
Gesi C; Paletta S; Palazzo MC; Dell'Osso B; Mencacci C; Cerveri G
Neuropsychiatr Dis Treat; 2021; 17():3581-3588. PubMed ID: 34908838
[TBL] [Abstract][Full Text] [Related]
19. The Role of Dopamine D
Huang M; He W; Kiss B; Farkas B; Adham N; Meltzer HY
J Pharmacol Exp Ther; 2019 Nov; 371(2):517-525. PubMed ID: 31511365
[TBL] [Abstract][Full Text] [Related]
20. Cariprazine to Treat Schizophrenia and Bipolar Disorder in Adults.
Edinoff A; Ruoff MT; Ghaffar YT; Rezayev A; Jani D; Kaye AM; Cornett EM; Kaye AD; Viswanath O; Urits I
Psychopharmacol Bull; 2020 Sep; 50(4):83-117. PubMed ID: 33012874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
